Efficacy and Safety of Lecanemab in Treating Alzheimer's Disease: A Real‐World Study in South China

Abstract

Background: Lecanemab is the only monoclonal antibody currently available that targets soluble amyloid‐beta (Aβ) protofibrils. It was introduced in China in 2024, but its real‐world efficacy remains to be demonstrated. This study aims to evaluate the efficacy and safety of Lecanemab in real‐world practice in South China.

The paper